{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:14:41Z","timestamp":1788513281988,"version":"build-2803163510"},"reference-count":41,"publisher":"American Chemical Society (ACS)","issue":"11","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccbyncnd_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005928","name":"Daiwa Securities Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003837","name":"Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24390010"],"award-info":[{"award-number":["24390010"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008965","name":"Takahashi Industrial and Economic Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pemetrexed (PMX) is a key drug for the management of malignant pleural mesothelioma (MPM). However, its therapeutic efficacy is cruelly restricted in many clinical settings by the overexpression of thymidylate synthase (TS) gene. Recently, we emphasized the efficacy of locally administered shRNA designed against TS gene in enhancing the cytotoxic effect of PMX against orthotopically implanted MPM cells in tumor xenograft tumor model. Herein, we explored the efficiency of systemic, rather than local, delivery of TS RNAi molecule in sensitizing MPM cells to the cytotoxic effect of PMX. We here designed a PEG-coated TS shRNA-lipoplex (PEG-coated TS shRNA-lipoplex) for systemic injection. PEG modification efficiently delivered TS shRNA in the lipoplex to tumor tissue following intravenous administration as indicated by a significant suppression of TS expression level in tumor tissue. In addition, the combined treatment of PMX with systemic injection of PEG-coated TS shRNA-lipoplex exerted a potent antitumor activity in a s.c. xenograft tumor model, compared to a single treatment with either PMX or PEG-coated TS shRNA-lipoplex. Metastasis, or the spread, of mesothelioma substantially dedicates the effectiveness of treatment options. The systemic, in addition to local, delivery of tumor targeted anti-TS RNAi system we propose in this study might be an effective option to extend the clinical utility of PMX in treating malignant mesothelioma.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6b00728","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T16:22:38Z","timestamp":1476462158000},"page":"3955-3963","source":"Crossref","is-referenced-by-count":10,"title":["Systemically Administered RNAi Molecule Sensitizes\nMalignant Pleural Mesotheliomal Cells to Pemetrexed Therapy"],"prefix":"10.1021","volume":"13","author":[{"given":"Amr S.","family":"Abu Lila","sequence":"first","affiliation":[{"name":"Tokushima University , , ,","place":["Tokushima, Japan"]},{"name":"Zagazig University , , ,","place":["Zagazig, Egypt, 44519"]},{"name":"Hail University , , ,","place":["Hail, Saudi Arabia, 2440"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Tokushima University , , ,","place":["Tokushima, Japan, 770-8505"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Long","family":"Huang","sequence":"additional","affiliation":[{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Wada","sequence":"additional","affiliation":[{"name":"Kyoto University , , ,","place":["Kyoto, Japan, 606-8501"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[{"name":"Tokushima University , , ,","place":["Tokushima, Japan"]},{"name":"Tokushima University , , ,","place":["Tokushima, Japan, 770-8505"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2016,10,14]]},"reference":[{"issue":"14","key":"2026090403124031700_cit1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of\npemetrexed in combination with cisplatin versus cisplatin alone in\npatients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"2026090403124031700_cit2","doi-asserted-by":"publisher","first-page":"32992","DOI":"10.1038\/srep32992","article-title":"PI3 Kinase Pathway\nand MET Inhibition is Efficacious in Malignant Pleural Mesothelioma","volume":"6","author":"Kanteti","year":"2016","journal-title":"Sci. Rep."},{"key":"2026090403124031700_cit3","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12885-016-2745-8","article-title":"Malignant mesothelioma\nof the pleura with desmoplastic histology: a case series and literature\nreview","volume":"16","author":"Hashimoto","year":"2016","journal-title":"BMC Cancer"},{"issue":"2","key":"2026090403124031700_cit4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jtcvs.2009.11.072","article-title":"Prevalence\nof in vitro chemotherapeutic drug resistance in primary malignant\npleural mesothelioma: result in a cohort of 203 resection specimens","volume":"140","author":"Mujoomdar","year":"2010","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"9","key":"2026090403124031700_cit5","doi-asserted-by":"publisher","first-page":"rjt087","DOI":"10.1093\/jscr\/rjt087","article-title":"Cerebral metastasis from malignant\npleural mesothelioma","volume":"2013","author":"El Molla","year":"2013","journal-title":"J. Surg Case Rep"},{"issue":"8","key":"2026090403124031700_cit6","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II\nstudy of pemetrexed with and without folic acid and vitamin B12 as\nfront-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"2026090403124031700_cit7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin\nor pemetrexed plus carboplatin for chemonaive patients with malignant\npleural mesothelioma: results of the International Expanded Access\nProgram","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"2026090403124031700_cit8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1146\/annurev.bi.64.070195.003445","article-title":"The catalytic mechanism\nand structure of thymidylate\nsynthase","volume":"64","author":"Carreras","year":"1995","journal-title":"Annu. Rev. Biochem."},{"key":"2026090403124031700_cit9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/1471-2407-8-348","article-title":"Effects of small interfering RNA\ntargeting thymidylate synthase on survival of ACC3 cells from salivary\nadenoid cystic carcinoma","volume":"8","author":"Shirasaki","year":"2008","journal-title":"BMC Cancer"},{"issue":"3","key":"2026090403124031700_cit10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0006-2952(03)00287-9","article-title":"Induction of resistance\nto the multitargeted antifolate\nPemetrexed (ALIMTA) in WiDr human colon cancer cells is associated\nwith thymidylate synthase overexpression","volume":"66","author":"Sigmond","year":"2003","journal-title":"Biochem.\nPharmacol."},{"issue":"4","key":"2026090403124031700_cit11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1124\/mol.107.042382","article-title":"Molecular mechanisms\nunderlying the synergistic interaction\nof erlotinib, an epidermal growth factor receptor tyrosine kinase\ninhibitor, with the multitargeted antifolate pemetrexed in non-small-cell\nlung cancer cells","volume":"73","author":"Giovannetti","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"10","key":"2026090403124031700_cit12","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/bjc.2011.129","article-title":"Thymidylate synthase as a determinant\nof pemetrexed sensitivity in non-small cell lung cancer","volume":"104","author":"Takezawa","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"4C","key":"2026090403124031700_cit13","first-page":"3575","article-title":"MDR1 and thymidylate synthase (TS) gene expressions\nin advanced breast cancer: relationships to drug exposure, p53 mutations,\nand clinical outcome of the patients","volume":"19","author":"Lizard-Nacol","year":"1999","journal-title":"Anticancer\nRes."},{"issue":"4","key":"2026090403124031700_cit14","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3892\/ijo.2016.3367","article-title":"Downregulation of thymidylate\nsynthase by RNAi molecules enhances the antitumor effect of pemetrexed\nin an orthotopic malignant mesothelioma xenograft mouse model","volume":"48","author":"Abu Lila","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"3","key":"2026090403124031700_cit15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10585-015-9772-8","article-title":"Brain metastasis\nin malignant pleural mesothelioma","volume":"33","author":"Yamagishi","year":"2016","journal-title":"Clin. Exp.\nMetastasis"},{"issue":"7","key":"2026090403124031700_cit16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2169\/internalmedicine.55.3765","article-title":"Brain Metastasis of\nPleural Mesothelioma\nafter a Subarachnoid Hemorrhage","volume":"55","author":"Hirooka","year":"2016","journal-title":"Intern. Med."},{"key":"2026090403124031700_cit17","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12874","article-title":"Malignant\npleural fluid from mesothelioma has potent biological activities","author":"Cheah","year":"2016","journal-title":"Respirology"},{"key":"2026090403124031700_cit18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/IJN.S10462","article-title":"In vitro\nand in vivo effects of polyethylene\nglycol (PEG)-modified lipid in DOTAP\/cholesterol-mediated gene transfection","volume":"5","author":"Gjetting","year":"2010","journal-title":"Int. J. Nanomed."},{"key":"2026090403124031700_cit19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejps.2015.09.015","article-title":"Encapsulation in a rapid-release liposomal formulation\nenhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft\nmodel","volume":"81","author":"Eldin","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"2026090403124031700_cit20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery\nsystems: from concept to clinical\napplications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Delivery Rev."},{"issue":"2","key":"2026090403124031700_cit21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nrg2504","article-title":"Small silencing RNAs: an expanding universe","volume":"10","author":"Ghildiyal","year":"2009","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"2026090403124031700_cit22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.bbrc.2008.01.074","article-title":"Disappearance of the angiogenic potential\nof endothelial cells caused by Argonaute2 knockdown","volume":"368","author":"Asai","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"2026090403124031700_cit23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1248\/bpb.30.972","article-title":"In vitro efficacy of\na sterically stabilized immunoliposomes\ntargeted to membrane type 1 matrix metalloproteinase (MT1-MMP)","volume":"30","author":"Atobe","year":"2007","journal-title":"Biol. Pharm. Bull."},{"issue":"11","key":"2026090403124031700_cit24","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/mt.2011.174","article-title":"A double-modulation strategy in cancer\ntreatment with\na chemotherapeutic agent and siRNA","volume":"19","author":"Nakamura","year":"2011","journal-title":"Mol. Ther."},{"issue":"3","key":"2026090403124031700_cit25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0021-9258(18)70227-5","article-title":"Colorimetric\nassay methods for free and phosphorylated glyceric acids","volume":"234","author":"Bartlett","year":"1959","journal-title":"J. Biol. Chem."},{"issue":"1","key":"2026090403124031700_cit26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0014-5793(99)01320-4","article-title":"A combinatorial approach to producing\nsterically stabilized (Stealth) immunoliposomal drugs","volume":"460","author":"Ishida","year":"1999","journal-title":"FEBS Lett."},{"issue":"1","key":"2026090403124031700_cit27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2009.02.023","article-title":"Oxaliplatin encapsulated in PEG-coated\ncationic liposomes induces significant tumor growth suppression via\na dual-targeting approach in a murine solid tumor model","volume":"137","author":"Abu Lila","year":"2009","journal-title":"J. Controlled Release"},{"issue":"1","key":"2026090403124031700_cit28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/pst.369","article-title":"Interval approach\nto assessing antitumor activity for\ntumor xenograft studies","volume":"9","author":"Wu","year":"2010","journal-title":"Pharm. Stat"},{"issue":"4","key":"2026090403124031700_cit29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/ijc.25716","article-title":"Overexpression of SOCS3 exhibits\npreclinical antitumor activity against\nmalignant pleural mesothelioma","volume":"129","author":"Iwahori","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"7","key":"2026090403124031700_cit30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/bdd.2510140706","article-title":"Kinetic analysis of\ntissue distribution of doxorubicin\nincorporated in liposomes in rats (II)","volume":"14","author":"Harashima","year":"1993","journal-title":"Biopharm.\nDrug Dispos."},{"key":"2026090403124031700_cit31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1471-2407-14-304","article-title":"Cisplatin-resistant\ncells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+)\nphenotype and sphere-forming capacity","volume":"14","author":"Cortes-Dericks","year":"2014","journal-title":"BMC Cancer"},{"issue":"8","key":"2026090403124031700_cit32","doi-asserted-by":"publisher","first-page":"e40521","DOI":"10.1371\/journal.pone.0040521","article-title":"Molecular\nresistance fingerprint of pemetrexed and platinum in a long-term survivor\nof mesothelioma","volume":"7","author":"Roe","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"2026090403124031700_cit33","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2003.02.043","article-title":"Pemetrexed\nand cisplatin for malignant pleural mesothelioma: a new standard of\ncare?","volume":"21","author":"Rusch","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"2026090403124031700_cit34","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/JTO.0b013e318260deaa","article-title":"Folylpoly-Glutamate\nSynthetase Expression Is Associated\nwith Tumor Response and Outcome from Pemetrexed-Based Chemotherapy\nin Malignant Pleural Mesothelioma","volume":"7","author":"Christoph","year":"2012","journal-title":"J. Thorac.\nOncol."},{"issue":"8","key":"2026090403124031700_cit35","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing\ngroup-1 as predictors of responsiveness in mesothelioma patients treated\nwith pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"2026090403124031700_cit36","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation\ngroup 1 tumor expression predicts outcome in patients with malignant\npleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Righi","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2\u20133","key":"2026090403124031700_cit37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0925-4439(02)00082-0","article-title":"Induction of thymidylate synthase\nas a 5-fluorouracil\nresistance mechanism","volume":"1587","author":"Peters","year":"2002","journal-title":"Biochim. Biophys. Acta,\nMol. Basis Dis."},{"issue":"3","key":"2026090403124031700_cit38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1200\/JCO.2004.05.064","article-title":"Thymidylate synthase expression and\nprognosis in colorectal cancer: a systematic review and meta-analysis","volume":"22","author":"Popat","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"2026090403124031700_cit39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2967\/jnumed.109.066878","article-title":"In vivo imaging\nof RNA interference","volume":"51","author":"Hong","year":"2010","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026090403124031700_cit40","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.addr.2009.04.018","article-title":"siRNA delivery systems\nfor cancer treatment","volume":"61","author":"Oh","year":"2009","journal-title":"Adv. Drug Delivery Rev."},{"issue":"2","key":"2026090403124031700_cit41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3892\/ijo.2010.880","article-title":"Combined therapy with a thymidylate synthase-inhibiting vector and\nS-1 has effective antitumor activity against 5-FU-resistant tumors","volume":"38","author":"Kadota","year":"2011","journal-title":"Int. J. Oncol."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6b00728","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/13\/11\/3955\/67341435\/acs.molpharmaceut.6b00728.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/13\/11\/3955\/67341435\/acs.molpharmaceut.6b00728.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:28:06Z","timestamp":1788510486000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/13\/11\/3955\/1677989\/Systemically-Administered-RNAi-Molecule-Sensitizes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,14]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,10,14]]},"published-print":{"date-parts":[[2016,11,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00728","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,14]]}}}